The Scienture Holdings, Inc. (NASDAQ: SCNX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy materials and registration-related documents. Scienture files with the U.S. Securities and Exchange Commission as a Delaware corporation under Commission File Number 001-39199, and its filings offer detailed insight into its specialty pharmaceutical business conducted through its wholly owned subsidiary, Scienture, LLC.
Among the most informative documents for SCNX are current reports on Form 8-K, which describe material events such as financing arrangements, amendments to debt agreements, conversion of secured convertible debentures into common stock, and the issuance of senior secured promissory notes. These filings outline key terms such as principal amounts, original issue discounts, interest rates, security agreements granting liens on company and subsidiary assets, and guaranty obligations. Other 8-Ks address corporate actions including amendments to bylaws, notices from Nasdaq regarding minimum bid price compliance, and results of stockholder votes at the annual meeting.
Scienture’s definitive proxy statement on Schedule 14A is another core filing, setting out proposals submitted to stockholders, including director elections, potential increases in authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), and possible reverse stock split authority. The proxy statement also explains governance structures, committee charters and procedures for the annual meeting.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex topics such as capital structure changes, equity distribution agreements on Form S-3, or listing compliance matters. Users can review historical and recent filings, monitor how Scienture manages its financing and governance, and reference official disclosures related to its specialty products, including Arbli™ and REZENOPY™. This page is a resource for investors seeking structured, regulator-reviewed information on SCNX beyond press releases and market commentary.
Scienture Holdings (SCNX) filed its Q3 2025 report, showing early commercial activity with revenues of $590,050 in the quarter (vs. $64,861 a year ago) and $600,308 for the nine months (vs. $83,560). Gross profit was $574,621 for Q3, but higher operating costs led to an operating loss of $4,361,206 and a net loss of $3,607,361. Weighted average shares were 18.96 million in Q3.
The balance sheet reflects the 2024 Scienture acquisition with $76.4 million in product technology intangibles and $21.37 million of goodwill. Cash was $355,692 at September 30, 2025, and accumulated deficit was $52,430,904. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
As part of a strategic realignment, the company sold IPS, Softell and Bonum Health on April 30, 2025 in exchange for a $5,000,000 promissory note (prime rate, balloon due June 30, 2030), recording a $385,528 loss on disposition and $62,500 of interest income. Common shares outstanding were 23,132,260 as of September 30, 2025; the company reports 40,630,815 shares outstanding on November 12, 2025.
Scienture Holdings, Inc. launched an at-the-market equity program to sell up to $150,000,000 of common stock, with Maxim Group LLC as sales agent under its S-3 shelf.
Sales may occur on Nasdaq or through other permitted methods at prevailing prices, and Maxim will earn a 3.0% commission. The company previously sold 15,722,759 shares for gross proceeds of approximately $15,568,236 under earlier supplements. The last reported sale price was $0.75 per share on November 6, 2025.
Shares outstanding were 40,630,815 prior to this program; the filing illustrates a hypothetical post‑offering share count of 240,630,815 if 200,000,000 shares were sold at $0.75. The company’s authorized common stock is 100,000,000 shares and it will not issue above that amount; the board has recommended increasing authorization to 2,000,000,000 shares. Net proceeds are intended for working capital and general corporate purposes, including R&D, commercialization, potential debt repayment, and possible acquisitions.
Scienture Holdings (SCNX) filed a prospectus supplement increasing the amount it may sell under its Form S-3, General Instruction I.B.6, and its equity distribution agreement with Maxim Group LLC to an aggregate offering price of up to $9,592,009.
The company reports it has sold approximately $13,252,250 in gross proceeds of securities under I.B.6 during the prior 12 months. The prospectus supplement states that $9,592,009 remains available to be sold. This notice is not an offer to sell or a solicitation to buy, and any sales would relate to the company’s common stock, par value $0.00001 per share, on permitted terms and in compliant jurisdictions.
Scienture Holdings filed an amended prospectus supplement to register the offer and sale of up to $9,592,009 of common stock, from time to time through Maxim Group LLC under its at-the-market program pursuant to Form S-3.
The amendment increases the amount eligible to be sold under General Instruction I.B.6, which limits primary offerings to no more than one-third of public float while it remains below $75,000,000. The company has sold approximately $13,252,250 during the prior 12 months, leaving $9,592,009 available under the Sales Agreement.
Shares trade on Nasdaq as SCNX; the last reported price was $2.60 per share on October 23, 2025. Shares outstanding were 34,474,230 as of October 23, 2025, and the aggregate market value of non-affiliate holdings used for the I.B.6 calculation was approximately $68,601,377.
Scienture Holdings (SCNX) amended executive employment agreements. Effective October 1, 2025, the company increased base salaries and enhanced severance terms for Co‑CEOs Dr. Narasimhan Mani and Dr. Shankar Hariharan. Dr. Mani’s annual base rose from $325,000 to $400,000; Dr. Hariharan’s rose from $175,000 to $400,000, each subject to periodic Compensation Committee review.
Severance if terminated without Cause or for Good Reason increased from 12 months to 24 months of base salary, and, within 12 months after a Change in Control, from 1.5x to 2x the sum of base salary (then‑current or pre‑CIC), target annual incentive for the year, and discretionary bonus. Health insurance employer contributions (COBRA) and life insurance premium payments were extended from 12 to 24 months post‑termination. The amendments also formalize Dr. Mani as President and Co‑CEO and Dr. Hariharan as Executive Chairman and Co‑CEO.
Scienture Holdings (SCNX) set its virtual annual meeting for November 12, 2025. Stockholders will vote on six proposals that reshape capital structure and financing flexibility.
Key items include: increasing authorized common shares from 100,000,000 to 2,000,000,000 and preferred from 10,000,000 to 200,000,000 (Proposal 2); expanding the 2019 Equity Incentive Plan reserve from 5,000,000 to 25,000,000 shares (Proposal 3); and pre-approving a potential private financing of up to $500,000,000 that may be priced at up to a 50% discount under Nasdaq Rule 5635(d) (Proposal 4). The Board also seeks discretion to effect a reverse stock split between 1-for-2 and 1-for-50 to support Nasdaq’s $1.00 minimum bid requirement after receiving a notice on October 14, 2025, with a compliance deadline of April 13, 2026 (Proposal 5). Proposal 6 would allow adjournment to solicit additional proxies. Directors for one-year terms are up for election in Proposal 1.
Scienture Holdings (SCNX) disclosed it received a Nasdaq notice that its common stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period. The company has 180 calendar days, until April 13, 2026, to regain compliance by maintaining a closing bid at or above $1.00 for at least ten consecutive business days.
The notice has no immediate effect on the listing or trading of the stock on Nasdaq. Scienture believes it can regain compliance, while noting there is no assurance it will meet the requirement or other Nasdaq criteria.
Scienture Holdings (SCNX) refinanced debt and added new funding. The company entered a note purchase with Streeterville Capital for a senior secured promissory note with principal of $3,911,111.11, carrying an original issue discount of $391,111.11 and net proceeds of $3,500,000. The note bears 9% annual interest, is due seven months after issuance, and can be prepaid without penalty. Proceeds were used to repay the remaining balance of the prior NVK loan, with the remainder allocated to working capital, debt repayment, capital expenditures, product development, and general purposes. The note is secured by all assets of the company and its subsidiary, with a subsidiary guaranty, and includes a mandatory prepayment equal to the lesser of 25% of any future capital raised or the full amount due.
Separately, the company amended the NVK loan, extending its maturity to December 8, 2025 and obtaining a waiver of existing events of default. As of September 30, 2025, the outstanding NVK balance was $2,656,250. Consideration included fees of $25,000 at signing, a $25,000 maturity extension fee, and issuance of 250,000 common shares, with the company agreeing to register the resale. As of October 15, 2025, all NVK obligations were repaid.
Scienture Holdings, Inc. preliminary proxy statement presents several governance and capital-structure proposals for stockholder vote. Key items include a proposal to increase authorized Common Stock from 100,000,000 to 2,000,000,000 shares and Preferred Stock from 10,000,000 to 200,000,000, and a proposed amendment to increase shares available under the 2019 Equity Incentive Plan from 5,000,000 to 25,000,000. The proxy also seeks approval for a potential future offering that could issue more than 20% of currently outstanding common shares at a price below Nasdaq's defined "minimum price."
The document lists director nominees with ages and term expirations, describes a potential Reverse Stock Split with cash in lieu of fractional shares, and details insider trading and anti-hedging policies restricting trades to approved windows or 10b5-1 plans and prohibiting short sales. Vesting and forfeiture terms for restricted stock and administrator discretion to accelerate vesting are explained. Several annexes and committee rules are referenced but not fully reproduced in the excerpt.
Scienture Holdings, Inc. amended its bylaws to lower the shareholder meeting quorum requirement from a majority of voting power to one-third of the voting power. This means future stockholder meetings can proceed and conduct business with fewer shares represented in person, remotely, or by proxy, unless a higher threshold is required by law, the certificate of incorporation, or other bylaw provisions. The rules allowing the chairperson or a majority of voting power present to adjourn meetings until a quorum is reached remain in place.